RPG Life Sciences Limited announced the Investor Presentation for the RPG Annual Investor Conference 2025, scheduled to be held on June 03, 2025. The presentation highlights the company's strong performance in FY25 and outlines its strategic roadmap for future growth.

Key financial and operational highlights for FY25 include:

• Sales growth of 6.6% and EBITDA growth of 27.3% compared to the previous year.
• EBITDA margin expanded to 26.4% in FY25 from 23.3% in FY24, reflecting improved cost efficiencies.
• Profit Before Tax (PBT) increased by 28% to ₹150.3 crore in FY25 from ₹117.8 crore in FY24.
• Revenue reached ₹653.4 crore in FY25, up from ₹582.1 crore in FY24, marking a 12% increase.
• Earnings Per Share (EPS) stood at ₹67.5, Return on Capital Employed (ROCE) at 32.9%, and Return on Equity (ROE) at 24.3% for FY25.
• The company maintained a zero-debt status and reported a significant surplus cash flow of ₹267 crore in FY25.
• RPG Life Sciences' market capitalization has outperformed benchmarks over the past five years, growing 13.2x compared to BSE Healthcare (3.5x) and BSE Sensex (2.7x).
• ICRA reaffirmed the company's long-term rating at A+ with a stable outlook and short-term rating at A1, citing strong brands, steady growth, robust capital structure, and healthy cash flows.

Strategic initiatives enabling strong performance:

• Naprosyn brand crossed ₹76 crore in FY25 and is on track to become a ₹100 crore brand.
• The new rheumatology franchise contributes 14% to the specialty business, with a foray into ortho and critical care.
• Ongoing projects to build cost efficiencies, contributing to margin expansion.
• Obtained TGA and EUGMP certification renewals in FY25.
• Invested approximately ₹140 crore in capex for plant and R&D infrastructure modernization.
• Evaluating opportunities for inorganic growth utilizing its significant cash reserves.
• Demonstrated strong environmental performance with a 41% carbon emission reduction, 41% increase in energy efficiency, 52% reduction in hazardous waste, and 7% reduction in water consumption in FY25.

The company's journey ahead is guided by seven strategic pillars:

• Portfolio development and building mega-brands, including growing the immunosuppressant portfolio to over ₹200 crore and Naprosyn to over ₹100 crore.
• Growing the API business by focusing on new geographies, launch pipelines, and manufacturing productivity.
• Implementing a strong digital roadmap to streamline operations and improve efficiency.
• Actively evaluating Mergers & Acquisitions opportunities with defined criteria for growth synergy.
• Developing new products across segments and expanding into new therapies.
• Focusing on talent development and acquisition across key business and support functions.
• Leveraging state-of-the-art capacity plants, supported by ₹140 crore capex since FY22, to enhance manufacturing productivity.